Al-Khateeb Alyaa, Mohamed Mohd Sapawi, Imran Kamarul, Ibrahim Suhairi, Zilfalill B A, Yusof Zurkurnai
Human Genome Centre, Kubang Kerian, Kelantan, Malaysia.
Southeast Asian J Trop Med Public Health. 2011 Mar;42(2):388-94.
The aim of the present study was to evaluate Malaysian dyslipidemic patient treatment practices and outcomes. Factors contributing to success in reaching treatment goal were determined. A retrospective review of the records of dyslipidemic patients who attended the Universiti Sains Malaysia Hospital in 2007 was conducted. All the patients were receiving standard recommended doses of statins. Records were analysed for 890 patients. Patients were divided into three categories: 384 patients (43.1%) had coronary heart disease or coronary heart disease risk equivalents, 216 patients (24.3%) had moderate risk for coronary heart disease and 290 patients (32.6%) had low risk. Statins were the most commonly prescribed drug group (92%), of which atorvastatin was the most commonly prescribed drug (50.6%). The overall success rate for reaching goal was 64.2%. The percentages of patients achieving low-density lipoprotein cholesterol targets in the coronary heart disease and coronary heart disease risk equivalents, moderate, and low-risk groups were 50.5, 66.7, and 80.3%, respectively (p < 0.001). Multiple logistic regression showed achievement of therapeutic goal declined with increasing risk group. The baseline low-density lipoprotein cholesterol value was inversely related to therapeutic goal attainment. An inadequate proportion of dyslipidemic patients achieved the National Cholesterol Education Program therapeutic goals for low-density lipoprotein cholesterol, especially those in the coronary heart disease and coronary heart disease risk equivalent group. The achievement of this goal was dependent on baseline low-density lipoprotein cholesterol levels.
本研究的目的是评估马来西亚血脂异常患者的治疗方法及治疗效果。确定了有助于实现治疗目标的因素。对2007年在马来西亚理科大学医院就诊的血脂异常患者的记录进行了回顾性分析。所有患者均接受标准推荐剂量的他汀类药物治疗。对890例患者的记录进行了分析。患者分为三类：384例（43.1%）患有冠心病或冠心病风险等同症，216例（24.3%）有中度冠心病风险，290例（32.6%）有低风险。他汀类药物是最常用的药物组（92%），其中阿托伐他汀是最常用的药物（50.6%）。实现目标的总体成功率为64.2%。冠心病和冠心病风险等同症组、中度风险组和低风险组中达到低密度脂蛋白胆固醇目标的患者百分比分别为50.5%、66.7%和80.3%（p<0.001）。多元逻辑回归显示，治疗目标的实现随着风险组的增加而下降。基线低密度脂蛋白胆固醇值与治疗目标的实现呈负相关。血脂异常患者中达到国家胆固醇教育计划低密度脂蛋白胆固醇治疗目标的比例不足，尤其是冠心病和冠心病风险等同症组的患者。这一目标的实现取决于基线低密度脂蛋白胆固醇水平。
